TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China ...

Investing.com -- TD Cowen downgraded Merck & Company Inc (NYSE:MRK) to "Hold" on concerns over uncertainty surrounding Gardasil sales, a slowdown in business development, and the looming loss of ...

today announced that company management will participate in the 45 th Annual TD Cowen Health Care Conference from March 3-5 in Boston, MA. Management will participate in a fireside chat on Tuesday ...

On Tuesday, TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in the endocrine market and the high potential of its product ...

TD Cowen analyst William Katz maintained a Hold rating on Artisan Partners (APAM – Research Report) today and set a price target of $46.00. The company’s shares closed yesterday at $45.32.

In a report released today, Daniel Bergman from TD Cowen maintained a Buy rating on Primerica (PRI – Research Report), with a price target of $345.00. The company’s shares closed yesterday at ...

TD Cowen analyst William Katz maintained a Buy rating on Invesco (IVZ – Research Report) today and set a price target of $22.00. The company’s shares closed yesterday at $18.74. Leverage the ...

In a report released today, Andrew Kligerman from TD Cowen maintained a Buy rating on W. R. Berkley Corporation (WRB – Research Report), with a price target of $73.00. The company’s shares ...

TD Cowen analyst William Katz maintained a Hold rating on Carlyle Group (CG – Research Report) today and set a price target of $54.00. The company’s shares closed yesterday at $49.58.

TD Cowen analyst Bill Katz lowered the firm’s price target on Carlyle (CG) to $54 from $57 and keeps a Hold rating on the shares. The firm lowered its estimates as the key take for Cowen is ...

TD Cowen raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $66 from $63 and keeps a Buy rating on the shares. The firm says Gomekli’s approval comes 17 days earlier than the ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with Gardasil’s challenges in China. It is ...